Co-Founder & CEO
Casey McPherson
Rose's father. Built To Cure A Rose Foundation, assembled the team that created Rosiphersen in under a year, and drives the company's vision, culture, and fundraising.
About Us
Our Story
AlphaRose Therapeutics was founded by Casey McPherson, lead singer and song-writer, entrepreneur and father to Rose. As a baby, Rose was diagnosed with a rare genetic disease.
Now eight years old, she has to face the world without words, scared by her seizures, unable to feed or take care of herself, and often alone.
Pioneering rare disease therapy
From a Father's Fight to a Global Solution: The Evolution of AlphaRose Therapeutics
Casey has been fighting for his daughter, and other children affected by genetic diseases, since 2018. He has become a leading voice in the rare disease field through his non-profit foundation To Cure A Rose Foundation, and Contract Research Organization, RareLabs. In under a year, Casey and his science team successfully developed a preclinical treatment for his daughter's disease.
Throughout this journey, Casey identified a critical need for an innovative business model in the biotech and pharmaceutical sectors to ensure that their process could reach millions of children like Rose — an area that many other companies have overlooked. In 2024, he founded AlphaRose Therapeutics to address this gap.
A new standard in precision medicine
Legendary Experience Meets Radical Innovation: The Vision Behind AlphaRose Therapeutics
Public-benefit corporation, AlphaRose Therapeutics, brings together Casey McPherson with industry leaders Belinda Termeer, Bassem Hassan, Yong-Lo, Brad Margus and others added alongside Henri Termeer at Genzyme in pioneering the field of rare disease biotech. Together, they are building a precision medicine company to change how the industry develops and commercializes genetic disease treatments.
Our Mission
To develop and commercialize genetic treatments for suffering patients of small populations.
Our Vision
To eradicate genetic disease by 2040 and usher in a new age of accessible personalized medicines for patients.
Our Legacy
To leverage decades of pioneering biotech expertise to bridge the gap between scientific discovery and global patient delivery.
The people behind this
Built by operators, not observers.
COO & President
Masako Nakamura
Brings 20+ years of operational leadership in biotech, having scaled organizations through clinical trials, commercial launch, and platform expansion.
Chief Scientific Officer
Robert Cabrera, Ph.D.
ASO chemistry pioneer with deep experience designing and validating individualized genetic medicines from sequence to clinic.
Head of R&D
Jeffrey Brown, Ph.D., MBA
Leads R&D strategy bridging discovery science and platform engineering, focused on making N-of-1 economically and operationally repeatable.
Head of Platform
Ala Mhanna, Ph.D.
Architects the AI and computational stack — Argus, MetaMorph, abcDNA, SOT Caller — that lets AlphaRose run individualized programs in parallel at scale.
Get in touch
We're Here to Help
Whether you have a project in mind, need guidance, or want to explore collaboration opportunities — reach out anytime. Our team will respond quickly and provide everything you need to move forward.